title: Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.
abstract: A promising approach to improving outcomes in patients with cryptococcal meningitis is to use adjunctive passive immunotherapy with a monoclonal antibody (MAb) directed against the capsular polysaccharide of Cryptococcus neoformans. This is the first application of MAb therapy for the treatment of a fungal disease in humans. We determined the safety and maximum tolerated dose of the murine anticryptococcal MAb 18B7 in a phase I dose-escalation study. The subjects were human immunodeficiency virus-infected patients who had been successfully treated for cryptococcal meningitis. Six dosing cohorts received MAb 18B7 at 0.01 to 2 mg/kg of body weight as a single infusion. Three patients each received 0.01, 0.05, 0.2, and 0.5 mg of MAb 18B7 per kg without significant adverse events. Four of the subjects who received the 1-mg/kg dose had mild study drug-associated toxicity, including transient nausea, vomiting, back pain, and urticarial rash. Two of the subjects who received 2 mg/kg developed drug-associated mild to moderate nausea, vomiting, chills, and myalgias. One of the subjects who received 2 mg/kg developed intracranial hypertension 10 weeks after MAb 18B7 administration. Serum cryptococcal antigen titers in the cohorts receiving doses of 1 and 2 mg/kg declined by a median of twofold at 1 week and a median of threefold at 2 weeks postinfusion, but the titers subsequently returned toward the baseline values by week 12. The half-life of MAb 18B7 in serum was approximately 53 h, while the MAb was undetectable in the cerebrospinal fluid of all patients. These data support the continued investigation of MAb 18B7 at a maximum single dose of 1.0 mg/kg.
authors.affiliation: Department of Medicine (Infectious Diseases), 2020 Zonal Ave., IRD Room 632, MC 9520, University of Southern California, Los Angeles, CA 90033, USA. rlarsen@usc.edu
authors.forename: Robert A
authors.initials: RA
authors.lastname: Larsen
authors.forename: Peter G
authors.initials: PG
authors.lastname: Pappas
authors.forename: John
authors.initials: J
authors.lastname: Perfect
authors.forename: Judith A
authors.initials: JA
authors.lastname: Aberg
authors.forename: Arturo
authors.initials: A
authors.lastname: Casadevall
authors.forename: Gretchen A
authors.initials: GA
authors.lastname: Cloud
authors.forename: Robert
authors.initials: R
authors.lastname: James
authors.forename: Scott
authors.initials: S
authors.lastname: Filler
authors.forename: William E
authors.initials: WE
authors.lastname: Dismukes
mesh_terms: D000818:Animals; D000908:Antibodies, Fungal / Q000009:adverse effects* / Q000276:immunology; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000493:pharmacokinetics; D000946:Antigens, Fungal / Q000097:blood; D019540:Area Under Curve; D003455:Cryptococcus neoformans / Q000276:immunology*; D015658:HIV Infections / Q000150:complications; D006801:Humans; D007116:Immunization, Passive; D016919:Meningitis, Cryptococcal / Q000628:therapy*; D051379:Mice
chemical_list: D000908:Antibodies, Fungal; D000911:Antibodies, Monoclonal; D000946:Antigens, Fungal
references.citation: J Infect Dis. 1991 May;163(5):1114-20
references.pmid: 2019759
references.citation: AIDS Res Hum Retroviruses. 1994 Sep;10(9):1079-87
references.pmid: 7826695
references.citation: Lancet. 1992 Jan 4;339(8784):21-3
references.pmid: 1370335
references.citation: Antimicrob Agents Chemother. 1992 Mar;36(3):690-2
references.pmid: 1622188
references.citation: Infect Immun. 1992 Nov;60(11):4534-41
references.pmid: 1398966
references.citation: J Immunol. 2000 Apr 15;164(8):4367-74
references.pmid: 10754337
references.citation: Infect Immun. 1995 Jul;63(7):2632-44
references.pmid: 7790079
references.citation: Infect Immun. 1995 Aug;63(8):2919-23
references.pmid: 7622213
references.citation: Infect Immun. 1995 Sep;63(9):3448-53
references.pmid: 7642276
references.citation: J Neuroimmunol. 1995 Oct;62(1):43-52
references.pmid: 7499491
references.citation: Antimicrob Agents Chemother. 1995 Jul;39(7):1398-405
references.pmid: 7492075
references.citation: J Clin Invest. 1996 Feb 1;97(3):689-98
references.pmid: 8609224
references.citation: J Infect Dis. 1996 May;173(5):1222-31
references.pmid: 8627076
references.citation: J Med Vet Mycol. 1996 Jan-Feb;34(1):19-30
references.pmid: 8786467
references.citation: Infect Immun. 1996 Jul;64(7):2846-9
references.pmid: 8698522
references.citation: Infect Immun. 1996 Aug;64(8):2897-903
references.pmid: 8757810
references.citation: Clin Infect Dis. 1995 Dec;21(6):1477-9
references.pmid: 8749638
references.citation: J Antimicrob Chemother. 1996 Mar;37(3):617-22
references.pmid: 9182119
references.citation: J Immunol. 1997 Jan 15;158(2):790-9
references.pmid: 8992996
references.citation: Infect Immun. 1997 May;65(5):1800-7
references.pmid: 9125564
references.citation: N Engl J Med. 1997 Jul 3;337(1):15-21
references.pmid: 9203426
references.citation: J Infect Dis. 1997 Aug;176(2):485-91
references.pmid: 9237716
references.citation: Antimicrob Agents Chemother. 1998 Jun;42(6):1437-46
references.pmid: 9624491
references.citation: Clin Infect Dis. 1999 Jan;28(1):82-92
references.pmid: 10028076
references.citation: AIDS. 1999 Apr 16;13(6):653-60
references.pmid: 10397559
references.citation: J Infect Dis. 1999 Sep;180(3):791-801
references.pmid: 10438368
references.citation: Am J Pathol. 1964 Jul;45:1-19
references.pmid: 14172716
references.citation: Arch Neurol. 1964 Dec;11:632-41
references.pmid: 14202180
references.citation: J Infect Dis. 1964 Oct;114:373-7
references.pmid: 14217937
references.citation: Arch Neurol. 1965 Feb;12:189-96
references.pmid: 14237776
references.citation: Med Mycol. 2000 Dec;38(6):407-17
references.pmid: 11204878
references.citation: J Immunol. 2002 Aug 1;169(3):1379-86
references.pmid: 12133962
references.citation: J Clin Microbiol. 2004 Jun;42(6):2786-8
references.pmid: 15184471
references.citation: Infect Immun. 1972 Jun;5(6):896-901
references.pmid: 4564405
references.citation: J Immunol. 1978 May;120(5):1686-90
references.pmid: 351055
references.citation: N Engl J Med. 1979 Jul 19;301(3):126-31
references.pmid: 449951
references.citation: Sabouraudia. 1981 Dec;19(4):237-44
references.pmid: 7034236
references.citation: J Immunol. 1982 Oct;129(4):1675-80
references.pmid: 7050244
references.citation: Infect Immun. 1987 Mar;55(3):749-52
references.pmid: 3546140
references.citation: Hybridoma. 1989 Apr;8(2):231-9
references.pmid: 2785482
references.citation: Ann Intern Med. 1990 Aug 1;113(3):183-7
references.pmid: 2197908
references.citation: J Exp Med. 1993 Apr 1;177(4):1105-16
references.pmid: 8459205
references.citation: Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3636-40
references.pmid: 8475112
references.citation: J Immunother Emphasis Tumor Immunol. 1994 Jan;15(1):42-52
references.pmid: 8110730
references.citation: Infect Immun. 1994 Mar;62(3):1079-88
references.pmid: 8112842
references.citation: Antimicrob Agents Chemother. 1994 Mar;38(3):580-7
references.pmid: 8203858
references.citation: Clin Infect Dis. 1994 Oct;19(4):741-5
references.pmid: 7803641
references.citation: Infect Immun. 1995 Feb;63(2):573-9
references.pmid: 7822024
references.citation: N Engl J Med. 1992 Jan 9;326(2):83-9
references.pmid: 1727236